Working languages:
English to Korean
Korean to English
French to Korean

Soohyun Jeong
Nanomedicine, IT, Biology

South Korea
Local time: 01:24 KST (GMT+9)

Native in: Korean Native in Korean
  • Send message through ProZ.com
Feedback from
clients and colleagues

on Willingness to Work Again info
No feedback collected
Account type Freelance translator and/or interpreter, Identity Verified Verified site user
Data security Created by Evelio Clavel-Rosales This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations This person is not affiliated with any business or Blue Board record at ProZ.com.
Services Translation
Expertise
Specializes in:
Medical: CardiologyChemistry; Chem Sci/Eng
Computers: SoftwareComputers: Systems, Networks
Engineering (general)IT (Information Technology)
Materials (Plastics, Ceramics, etc.)Medical: Pharmaceuticals
Medical: InstrumentsMedical: Health Care

Portfolio Sample translations submitted: 2
Korean to English: Title: permission change instruction(unification adjustment) on Mycophenolate Mofetil(oral dose) – call for opinion
General field: Medical
Detailed field: Medical (general)
Source text - Korean
Title: permission change instruction(unification adjustment) on Mycophenolate Mofetil(oral dose) – call for opinion

1.의약품 중 ‘미코페놀레이트모페틸 단일제(경구)’에 대하여 안전성․유효성 심사 등을 근거로 사용상의 주의사항을 붙임과 같이 통일조정할 예정임을 알려드리니,

2. 통일조정 대상품목 보유업체는 동 통일조정(안)에 대하여 이의가 있는 경우, 그 의견을 2015.07.27.(월)까지 우리 원(의약품심사조정과)에 제출하여 주시기 바라며, 관련 단체는 각 회원사에게 이 건 내용을 통지하여 통일조정 대상품목 보유업체가 아니더라도 별도 의견이 있는 경우 그 의견을 제출할 수 있도록 적극 협조하여 주시기 바랍니다.

3. 아울러 동 통일조정(안) 등 관련 내용은 우리 처 홈페이지(www.mfds.go.kr)> 알림마당> 공지사항에 게재할 예정임을 알려드리니, 각 회원사 통지 시 이를 활용하여 주시기 바랍니다.

※ 별도로 사용상의 주의사항이 설정된 첨가제를 함유한 품목에 대하여는 「의약품의 품목허가•신고•심사 규정」 제17조 제1항에 따라 최신의 안전성 관련 사항이 모두 기재될 수 있도록 자체적으로 관리할 것


붙임
1. 미코페놀레이트모페틸 단일제(경구) 통일조정 대상품목
2. 미코페놀레이트모페틸 단일제(경구_정제, 캡슐제) 변경대비표
3. 미코페놀레이트모페틸 단일제(경구_정제, 캡슐제) 통일조정(안)
4. 미코페놀레이트모페틸 단일제(경구_현탁액용 산제) 변경대비표
5. 미코페놀레이트모페틸 단일제(경구_현탁액용 산제) 통일조정(안)
6. 미코페놀레이트모페틸 단일제(경구) 허가사항 변경지시(통일조정)를 위한 의견조회. 끝.
Translation - English
Title: permission change instruction (unification adjustment) on Mycophenolate Mofetil single preparation (oral) – call for opinion

1. We notify that of all pharmaceuticals, ‘Mycophenolate Mofetil single preparation (oral)’ is scheduled to uniform adjustment of precaution in use, see attachment, referenced from safety.efficacy test
2. Moreover, any company in possession of target items thereof holds objection, it shall submit such opinion to us (Drug Review Management Division) before 07.27.2015, while related organization shall notify each member of this adjustment plan so any company, even if not in possession of target items, shall submit any opinion one might hold on this adjustment plan.
3. This unification adjustment (plan) and related subjects shall be up at our division’s webpage (www.mfds.go.kr)>notification board>notice which one can use upon noticing each corporate member.

※ Separately, for items that contain additives with the set precaution of use, shall be managed by a company itself to have latest safety materials registered under Article No.17 Paragraph No. 1 of 「Regulation on Pharmaceuticals Approval, Notification, and Review 」


attachment
1. unification adjustment on Mycophenolate Mofetil single preparation(oral) target items
2. Mycophenolate Mofetil single preparation(oral_tablet, capsule) comparison table for change
3. Mycophenolate Mofetil single preparation(oral_tablet, capsule) unification adjustment plan
4. Mycophenolate Mofetil single preparation(oral_powder for suspension) comparison table for change
5. Mycophenolate Mofetil single preparation(oral_powder for suspension) unification adjustment plan
6. Permission change instruction (unification adjustment) on Mycophenolate Mofetil single preparation (oral) – call for opinion.
Korean to English: Off-label Medicine evaluation procedure
General field: Medical
Detailed field: Medical: Pharmaceuticals
Source text - Korean
제1조(목적) 이 지침은 약사법에 의한 품목허가(신고)받은 범위 외로 사용하고자 하는 의약품의 안전성과 유효성을 평가하기 위한 평가대상, 평가절차 및 평가결과에 관한 사항을 정함으로써 허가외 사용 의약품 평가업무에 적정을 기함을 목적으로 한다.

제2조(정의) 이 지침에서 사용하는 용어의 뜻은 다음 각 호와 같다.
1. ‘허가외 사용 의약품’이란 약사법 제31조 제2항 및 제3항 또는 제42조 제1항에 의한 허가(신고)를 받았으나, 허가(신고)받지 아니한 효능•효과, 또는 용법•용량으로 사용하고자 하는 의약품을 말한다.
2. ‘신청자(기관)’란 이 지침 제3조 제1호 및 제2호에 따라 허가외 사용 의약품에 대한 안전성•유효성 평가를 요청한 자를 말한다.

제3조 (적용 대상) 이 지침에 따라 평가하는 허가외 사용 의약품은 다음과 같다.
1.「허가 또는 신고 범위 초과 약제 비급여 사용 승인에 관한 기준 및 절차」(보건복지부 고시)에 따라 건강보험심사평가원에서 검토 요청한 품목
2. 대한의사협회, 대한약사회 등 유관 단체에서 안전성과 유효성 평가가 필요하다고 검토 요청한 품목
3. 기타 안전성과 유효성에 관한 우려로 식품의약품안전처장이 검토가 필요하다고 인정한 품목
Translation - English
Article 1(Purpose) for the purpose of this evaluation procedure herein define the target, evaluation procedure, related subjects on evaluation results of Off-label Medicine per PHARMACEUTICALS AFFAIR ACT to evaluate safety and efficacy thereof and provide reasons to Off-label Medicine evaluation.

Article 2 (Definition) definitions of terms herein contained is as the following paragraph
1. ‘Off-label Medicine’ is pharmaceuticals approved(notified) in accordance to PHARMACEUTICALS AFFAIR ACT Article 31 Paragraph 2 and Paragraph 3 or Article 42 paragraph 1 that is subject to future use for effect•efficacy, or dose•dosage administration which has not been approved(notified).
2. ‘Applicant (Agency)’ is one who applied for safety and efficacy evaluation of Off-label Medicine following procedure herein, Article 3 Paragraph 1 and Paragraph 2

Article3 (Application) evaluation herein contained is applied to the following Off-label Medicine
1. Items that have been requested an assessment from Health Insurance Review & Assessment Service in accordance to 「Criteria and Procedures for the Approval of Non-reimbursement Use of Drugs Exceeding the Scope of Product Approval or Notification」(Ministry of Health and Welfare Announcement)
2. Items that have been requested evaluation on necessity basis for safety and efficacy thereof from Korean Medical Association, Korean Pharmaceutical Association, or from other relevant organization
3. Items that have been approved of the necessity of evaluation from Minister of Food and Drug Safety for other concerns on safety and efficacy.

Experience Years of experience: 3. Registered at ProZ.com: Jul 2018.
ProZ.com Certified PRO certificate(s) N/A
Credentials N/A
Memberships N/A
Software Adobe Acrobat, Adobe Illustrator, Microsoft Excel, Microsoft Word, OmegaT, Powerpoint
CV/Resume English (PDF)
Bio

BA in Biology and Ph.D. Student in Nanotechnology. Certified professional translator from International Interpretation & Translation Association of Korea. Part-time independent translator. Previous translation works include those in the field of psychology, Coursera subtitle for HR and IT courses, general business, and technology.

Keywords: korean, english, medicine, nanotechnology, biology, lifescience, HR, IT,


Profile last updated
Aug 16, 2018



More translators and interpreters: English to Korean - Korean to English - French to Korean   More language pairs